Octagon Therapeutics graduates from pilot project to research alliance with Novo Nordisk
After concluding a pilot under Novo Nordisk’s accelerator program, the US-based company is ready to take a bigger step with the Danish pharmaceutical giant.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
Novo Nordisk and Octagon Therapeutics, a US-based biotech company, have joined forces under a research alliance, according to a press release from earlier in September.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
